KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Non-Current Assets: 2009-2024

Historic Other Non-Current Assets for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $1.1 billion.

  • Regeneron Pharmaceuticals' Other Non-Current Assets rose 60.41% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 60.41%. This contributed to the annual value of $1.1 billion for FY2024, which is 155.80% up from last year.
  • Regeneron Pharmaceuticals' Other Non-Current Assets amounted to $1.1 billion in FY2024, which was up 155.80% from $444.1 million recorded in FY2023.
  • Regeneron Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $1.1 billion during FY2024, with a 5-year trough of $168.1 million in FY2020.
  • For the 3-year period, Regeneron Pharmaceuticals' Other Non-Current Assets averaged around $638.8 million, with its median value being $444.1 million (2023).
  • Data for Regeneron Pharmaceuticals' Other Non-Current Assets shows a peak YoY skyrocketed of 155.80% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' Other Non-Current Assets stood at $168.1 million in 2020, then increased by 28.55% to $216.1 million in 2021, then surged by 55.67% to $336.4 million in 2022, then surged by 32.02% to $444.1 million in 2023, then skyrocketed by 155.80% to $1.1 billion in 2024.